Evidence map›Paper›PMID 38679488›Full record

ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2024

Expression of inducible nitric oxide synthase, nitrotyrosine, eosinophilic peroxidase, eotaxin-3, and galectin-3 in patients with gastroesophageal reflux disease, eosinophilic esophagitis, and in healthy controls: a semiquantitative image analysis of 3,3'-diaminobenzidine-stained esophageal biopsies.

John Plate, Mogens Bove, Helen M Larsson, Elisabeth Norder Grusell, Nabanita Chatterjee, Leif E Johansson, Henrik Bergquist

Abstract read
In one paragraph

Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John PlateDepartment of Otorhinolaryngology, Head and Neck Surgery, NU-Hospital Group, Region Västra Götaland, Trollhättan, Sweden.ORCID 0009-0009-1988-2561
Mogens BoveDepartment of Otorhinolaryngology, Head and Neck Surgery, NU-Hospital Group, Region Västra Götaland, Trollhättan, Sweden.
Helen M LarssonDepartment of Otorhinolaryngology, Head and Neck Surgery, NU-Hospital Group, Region Västra Götaland, Trollhättan, Sweden.
Elisabeth Norder GrusellDepartment of Otorhinolaryngology, Head and Neck Surgery, Kungsbacka Hospital, Region Halland, Kungsbacka, Sweden.
Nabanita ChatterjeeCore Facilities, Centre for Cellular Imaging (CCI), University of Gothenburg, Gothenburg, Sweden.
Leif E JohanssonDepartment of ENT, Head and Neck Surgery, Skövde County Hospital, Region Västra Götaland, Skövde, Sweden.
Henrik BergquistDepartment of Otorhinolaryngology, Head and Neck Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic esophagitis (EoE) and gastroesophageal reflux disease (GERD) share many histopathological features; therefore, markers for differentiation are of diagnostic interest and may add to the understanding of the underlying mechanisms. The nitrergic system is upregulated in GERD and probably also in EoE. Esophageal biopsies of patients with EoE (n = 20), GERD (n = 20), and healthy volunteers (HVs) (n = 15) were exposed to antibodies against inducible nitric oxide synthase (iNOS), nitrotyrosine, eosinophilic peroxidase, eotaxin-3, and galectin-3. The stained object glasses were randomized, digitized, and blindly analyzed regarding the expression of DAB (3,3'-diaminobenzidine) by a protocol developed in QuPath software. A statistically significant overexpression of iNOS was observed in patients with any of the two inflammatory diseases compared with that in HVs. Eotaxin-3 could differentiate HVs versus inflammatory states. Gastroesophageal reflux patients displayed the highest levels of nitrotyrosine. Neither iNOS nor nitrotyrosine alone were able to differentiate between the two diseases. For that purpose, eosinophil peroxidase was a better candidate, as the mean levels increased stepwise from HVs via GERD to EoE. iNOS and nitrotyrosine are significantly overexpressed in patients with EoE and GERD compared with healthy controls, but only eosinophil peroxidase could differentiate the two types of esophagitis. The implications of the finding of the highest levels of nitrotyrosine among gastroesophageal reflux patients are discussed.

Indexed as

3,3'-DiaminobenzidineChemokine CCL26Eosinophilic EsophagitisEosinophil PeroxidaseGalectin 3Gastroesophageal RefluxNitric Oxide Synthase Type IITyrosineAdultAgedBiomarkersBiopsyCase-Control StudiesChemokine CCL24EsophagusFemale3,3'-Diaminobenzidine3-nitrotyrosineBiomarkersCCL26 protein, humanChemokine CCL24Chemokine CCL26Eosinophil PeroxidaseGalectin 3Nitric Oxide Synthase Type IINOS2 protein, humanTyrosineeosinophilic esophagitisgastroesophageal reflux diseaseimage analysisimmunohistochemistry

Identifiers

PMID38679488
PMCPMC11360979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.